2023 World Conference on Lung Cancer (Posters)-P2.13. Biomarkers for Predicting the Efficacy of PD-L1 Inhibitors Combined with Chemotherapy in ES-SCLC

P2.13. Biomarkers for Predicting the Efficacy of PD-L1 Inhibitors Combined with Chemotherapy in ES-SCLC - PDF(Slides)

Pdf Summary

This study aimed to explore validated efficacy predictors in patients with extensive-stage small cell lung cancer (ES-SCLC) receiving PD-L1 inhibitors combined with chemotherapy. The study included 251 patients diagnosed with ES-SCLC who received PD-L1 combination chemotherapy. Baseline characteristics such as gender, age, smoking history, TNM stage, PS score, PD-L1 expression, KI-67, NGS results, and organs of metastasis were collected. Blood tests and serum test results were recorded to calculate various biomarkers.<br /><br />The results showed that higher HGB levels predicted better overall survival (OS) and progression-free survival (PFS), while lower LDH levels were associated with good OS and PFS. Lower NLR (neutrophil-to-lymphocyte ratio) indicated better OS and PFS, while lower PLR (platelet-to-lymphocyte ratio) and SII (systemic immune-inflammation index) were associated with better PFS. Liver metastases, high LDH levels, and low HGB levels were identified as independent predictors of poor efficacy of PD-L1 inhibitors in ES-SCLC.<br /><br />Liver metastases were also associated with poor OS and PFS, while bone metastases predicted poor OS. Brain metastasis, however, did not have a prognostic value. Multivariate analysis confirmed that high LDH levels, low HGB levels, and liver metastases were independent factors for poor PFS and OS. <br /><br />In conclusion, this study identified biomarkers and clinical characteristics that can predict the efficacy of PD-L1 inhibitors in ES-SCLC. Higher LDH levels, lower HGB levels, and the presence of liver metastasis were associated with poor efficacy and negative prognosis. The positive correlation of lower NLR, PLR, and SII with PD-L1 efficacy requires further investigation.

Asset Subtitle

Xinghao Ai

Meta Tag

Speaker Xinghao Ai

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

ES-SCLC

PD-L1 inhibitors

chemotherapy

HGB levels

LDH levels

NLR

PLR

SII

metastasis

prognosis